Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data Immunovant, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2019
FY2020
FY2022
FY2023
FY2024
FY2025
FY2026
Research and development
25.7
47.9
68.6
102
160
213
361
457
General and administrative
2.69
18.2
39.5
54.2
48
57.3
77.2
76.2
Operating expenses
28.4
66.1
108
156
218
283
438
533
Interest expense
0.63
0
Other non-operating income
-0.16
0.41
0.33
-0.78
-0.25
-1.01
0.47
2.18
Pre-tax income
-28.6
-66.3
-108
-157
-211
-259
-413
-505
Income tax
0.02
0.1
-0.36
-0.08
0.01
0.57
0.89
0.22
Net income
-28.6
-66.4
-107
-157
-211
-259
-414
-506
EPS, basic
-1.29
-1.54
-1.22
-1.43
-1.71
-1.88
-2.73
-2.77
EPS, diluted
-1.29
-1.54
-1.22
-1.43
-1.71
-1.88
-2.73
-2.77
Shares, basic (weighted)
22.2
43.2
87.8
110
123
138
152
182
Shares, diluted (weighted)
22.2
43.2
87.8
110
123
138
152
182
Balance sheet
FY2019
FY2019
FY2020
FY2022
FY2023
FY2024
FY2025
FY2026
Cash and equivalents
6.99
101
400
494
377
635
714
902
Receivables
0.6
12.2
0.7
5.34
2.08
1.13
Other current assets
2.63
5.46
7.72
6.25
26.9
24.9
51.2
45.6
Total current assets
12.6
109
409
513
404
666
768
949
Property, plant and equipment
0.05
0.07
0.2
0.33
0.33
0.46
0.84
0.44
Lease right-of-use assets
0
3.28
2.3
1.17
0.13
0.1
0.07
Other non-current assets
0
7.62
7.75
Total assets
13.8
109
412
516
406
666
776
957
Accounts payable
0.21
1.19
2.43
18.6
1.35
7.16
17.7
7.54
Accrued liabilities
6.23
10.9
15.2
24.6
40.4
41.3
50.7
96.6
Total current liabilities
0.3
15.3
18.8
44.5
43.3
48.6
68.8
104
Lease liabilities
0
2.24
1.22
0.05
0
Total liabilities
6.49
15.3
21
45.7
43.3
48.6
68.8
104
Paid-in capital
31.8
185
590
825
928
1,442
1,945
2,597
Retained earnings
-24.8
-91.2
-199
-355
-566
-826
-1,240
-1,745
Other comprehensive income
0.35
-0.02
-0.3
0.4
0.85
1.91
1.46
0.73
Shareholders' equity
7.34
94.1
391
470
362
618
707
853
Total equity
7.34
94.1
391
470
362
618
707
853
Total liabilities and equity
13.8
109
412
516
406
666
776
957
Shares outstanding
38.6
54.7
98
116
130
146
170
204
Cash flow statement
FY2019
FY2019
FY2020
FY2022
FY2023
FY2024
FY2025
FY2026
Net income
-28.6
-66.4
-107
-157
-211
-259
-414
-506
Depreciation and amortization
0.01
0.02
0.07
0.13
0.19
0.23
0.38
0.41
Stock-based compensation
1.31
6.96
18.8
34.2
32.3
41.1
49.5
55.7
Deferred income tax
0
0
0
0
0
0
0
0
Change in receivables
-0.6
-11.6
11.8
-4.58
3.23
0.99
Cash from operations
-28.5
-53.4
-83.3
-106
-188
-214
-376
-407
Capital expenditures
-0.05
-0.03
-0.21
-0.25
-0.2
-0.36
-0.76
-0.01
Cash from investing
-0.05
-0.03
-0.21
-0.25
-0.2
-0.36
-0.76
-0.01
Stock issued
14.9
0
0.66
473
450
544
Cash from financing
35.6
147
383
200
70.9
472
454
596
Exchange rate effect
0
-0.09
0.22
0.99
0.75
-0.3
Net change in cash
6.99
93.6
300
93.7
-117
259
78.6
188
Free cash flow
-28.6
-53.4
-83.5
-106
-188
-215
-377
-407
Income taxes paid
0.07
0.06
0.17
0
0
0.51
1.2
2.39
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $33.30 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-73.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-63.1%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
20.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
33.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
16.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
23.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
33.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
18.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
20.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
14.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
15.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
7.27x
Current assets / current liabilities.
Quick ratio
6.82x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.81x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$2.02
Cash from operations / diluted weighted shares.
Book value per share
$3.57
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
9.35x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
9.35x
Market cap / tangible book value, when positive.
Earnings yield
-7.8%
Net income / market cap (the inverse of P/E).
Was Immunovant, Inc. profitable in fiscal 2026?
No. It reported a net loss of $505.6M.
How much free cash flow did Immunovant, Inc. generate in fiscal 2026?
Cash from operations of $407.3M minus capital expenditures of $8.0K left free cash flow of -$407.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.